Brief: Oncozenge Says Toxic Study With Bupivacaine Shows Good Margin Of Safety
25/08/2022 07:14
Aug 25 (Reuters) - Oncozenge AB ONCOZ.ST :
* ANNOUNCES THAT THE COMPANY'S TOXIC STUDY WITH BUPIVACAINE
SHOWS
GOOD MARGIN OF SAFETY FOR PLANNED DOSING OF BUPIZENGE AT
CONTINUOUS TREATMENT OVER SIX WEEKS.
Source text for Eikon: ID:nWkrTbp0n
Further company coverage: ONCOZ.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))